Graph Therapeutics Secures USD 3.1 Million Pre-Seed Funding
Deal News | Jan 17, 2025 | CEE Legal Matters
Graph Therapeutics, a Vienna-based company specializing in AI-driven drug discovery for inflammatory and immunological diseases, has successfully raised USD 3.1 million in a pre-seed financing round. This funding round was led by Squareone and Merantix Capital, with NAVEC Investment Management and other angel investors, including those from the Atomico Angel Program, also taking part. Legal advisory roles were fulfilled by multiple firms. Brandl Talos advised Graph Therapeutics, with their team comprising Partner Stephan Strass and Associate Lara Praethaler. NAVEC's legal interests were managed by Herbst Kinsky, led by Partner Philipp Kinsky. Squareone received counsel from Schoenherr, while further advisory for the Atomico Angel Program was provided by Fladgate. The funding aims to bolster Graph Therapeutics' endeavors in pioneering AI technologies for drug discovery applications.
Sectors
- Biotechnology
- Legal Services
- Venture Capital
Geography
- Austria – Graph Therapeutics is based in Vienna, Austria, marking it as the geographical focus for the biotech firm.
- Europe – The involvement of European investors and advisors, such as Squareone and Merantix Capital, positions the transaction within a broader European context.
Industry
- Biotechnology – Graph Therapeutics operates in AI-driven drug discovery, a niche within the biotechnology sector focusing on treatments for diseases.
- Legal Services – Multiple law firms, such as Brandl Talos, Herbst Kinsky, Schoenherr, and Fladgate, provided advisory services for the financing round.
- Venture Capital – The funding round was led by venture capital entities, Squareone and Merantix Capital, along with other investors.
Financials
- USD 3.1 Million – The total amount raised by Graph Therapeutics in the pre-seed financing round.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Graph Therapeutics | Target Company | Company | A Vienna-based company focusing on AI-driven drug discovery for inflammatory and immunological diseases. |
| Squareone | Lead Investor | Company | A venture capital firm leading the pre-seed funding round for Graph Therapeutics. |
| Merantix Capital | Co-Investor | Company | A venture capital firm participating in the funding round for Graph Therapeutics. |
| NAVEC Investment Management | Co-Investor | Company | An investment firm involved alongside other investors in the financing round for Graph Therapeutics. |
| Atomico Angel Program | Angel Investor | Company | A network of angel investors participating in the pre-seed funding of Graph Therapeutics. |
| Brandl Talos | Legal Advisor to Graph Therapeutics | Company | A law firm based in Vienna providing legal counsel to Graph Therapeutics for the transaction. |
| Stephan Strass | Partner at Brandl Talos | Person | A partner at Brandl Talos who advised Graph Therapeutics on the financing. |
| Lara Praethaler | Associate at Brandl Talos | Person | An associate at Brandl Talos involved in advising Graph Therapeutics. |
| Herbst Kinsky | Legal Advisor to NAVEC Investment Management | Company | A law firm that advised NAVEC Investment Management on the financing round. |
| Philipp Kinsky | Partner at Herbst Kinsky | Person | A partner at Herbst Kinsky who advised NAVEC on the financing. |
| Schoenherr | Legal Advisor to Squareone | Company | A law firm providing legal advisory services to Squareone for this transaction. |
| Fladgate | Legal Advisor to Atomico Angel Program | Company | A firm reportedly advising the Atomico Angel Program for their participation in the financing round. |